Barriers for orally inhaled therapeutic antibodies
INTRODUCTION: Respiratory diseases represent a worldwide health issue. The recent Sars-CoV-2 pandemic, the burden of lung cancer, and inflammatory respiratory diseases urged the development of innovative therapeutic solutions. In this context, therapeutic antibodies (Abs) offer a tremendous opportunity to benefit patients with respiratory diseases. Delivering Ab through the airways has been demonstrated to be relevant to improve their therapeutic index. However, few inhaled Abs are on the market.
AREAS COVERED: This review describes the different barriers that may alter the fate of inhaled therapeutic Abs in the lungs at steady state. It addresses both physical and biological barriers and discusses the importance of taking into consideration the pathological changes occurring during respiratory disease, which may reinforce these barriers.
EXPERT OPINION: The pulmonary route remains rare for delivering therapeutic Abs, with few approved inhaled molecules, despite promising evidence. Efforts must focus on the intertwined barriers associated with lung diseases to develop appropriate Ab-formulation-device combo, ensuring optimal Ab deposition in the respiratory tract. Finally, randomized controlled clinical trials should be carried out to establish inhaled Ab therapy as prominent against respiratory diseases.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
---|---|
Enthalten in: |
Expert opinion on drug delivery - 20(2023), 8 vom: 22. Juli, Seite 1071-1084 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Sécher, Thomas [VerfasserIn] |
---|
Links: |
---|
Themen: |
Biological barriers |
---|
Anmerkungen: |
Date Completed 02.11.2023 Date Revised 02.11.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1080/17425247.2023.2249821 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM36108398X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM36108398X | ||
003 | DE-627 | ||
005 | 20231226084408.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1080/17425247.2023.2249821 |2 doi | |
028 | 5 | 2 | |a pubmed24n1203.xml |
035 | |a (DE-627)NLM36108398X | ||
035 | |a (NLM)37609943 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Sécher, Thomas |e verfasserin |4 aut | |
245 | 1 | 0 | |a Barriers for orally inhaled therapeutic antibodies |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 02.11.2023 | ||
500 | |a Date Revised 02.11.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a INTRODUCTION: Respiratory diseases represent a worldwide health issue. The recent Sars-CoV-2 pandemic, the burden of lung cancer, and inflammatory respiratory diseases urged the development of innovative therapeutic solutions. In this context, therapeutic antibodies (Abs) offer a tremendous opportunity to benefit patients with respiratory diseases. Delivering Ab through the airways has been demonstrated to be relevant to improve their therapeutic index. However, few inhaled Abs are on the market | ||
520 | |a AREAS COVERED: This review describes the different barriers that may alter the fate of inhaled therapeutic Abs in the lungs at steady state. It addresses both physical and biological barriers and discusses the importance of taking into consideration the pathological changes occurring during respiratory disease, which may reinforce these barriers | ||
520 | |a EXPERT OPINION: The pulmonary route remains rare for delivering therapeutic Abs, with few approved inhaled molecules, despite promising evidence. Efforts must focus on the intertwined barriers associated with lung diseases to develop appropriate Ab-formulation-device combo, ensuring optimal Ab deposition in the respiratory tract. Finally, randomized controlled clinical trials should be carried out to establish inhaled Ab therapy as prominent against respiratory diseases | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Biological barriers | |
650 | 4 | |a PK/PD | |
650 | 4 | |a inhalation | |
650 | 4 | |a lungs | |
650 | 4 | |a mucus | |
650 | 4 | |a therapeutic antibody | |
700 | 1 | |a Heuzé-Vourc'h, Nathalie |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug delivery |d 2004 |g 20(2023), 8 vom: 22. Juli, Seite 1071-1084 |w (DE-627)NLM159019028 |x 1744-7593 |7 nnns |
773 | 1 | 8 | |g volume:20 |g year:2023 |g number:8 |g day:22 |g month:07 |g pages:1071-1084 |
856 | 4 | 0 | |u http://dx.doi.org/10.1080/17425247.2023.2249821 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 20 |j 2023 |e 8 |b 22 |c 07 |h 1071-1084 |